Surgical resection remains the cornerstone of management for chondrosarcoma and chordoma. However, the application of new biologic insights to therapeutic development indicates that improved ...
Inhibrx Biosciences is vying for approval of its targeted therapy, ozekibart, in chondrosarcoma. This follows the positive outcome of the Phase II ChonDRAgon trial (NCT04950075), which found that ...
SAN DIEGO, Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare ...
Chondrosarcoma is a malignant tumour characterised by the generation of a cartilaginous matrix by neoplastic cells. When occurring in the craniofacial region, particularly within the temporomandibular ...
Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results